Pharmaceutical development and manufacturing of a parenteral formulation of a novel antitumor agent, VNP40101M.
The objective of this study was to develop and manufacture a stable parenteral formulation for Phase I clinical trials of VNP40101M (1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-[(2-methylamino)carbonyl] hydrazine), a novel antitumor agent. The solubility and stability of the drug was determined. Solubility studies suggested that VNP40101M exhibited poor aqueous solubility but showed appreciable solubility in nonaqueous solvents. The aqueous solubility of the drug could not be increased by adjusting the pH. At a pH above 7, base-catalyzed decomposition of VNP40101M occurred. The low octanol-water partition coefficient of 0.75 suggested poor solubility in lipophilic solvents. Based on these preformulation observations, a parenteral formulation containing 10 mg/mL of VNP40101M was prepared in a solvent system consisting of 30% ethyl alcohol and 70% polyethylene glycol-300 (PEG-300). To minimize base-catalyzed hydrolytic degradation, citric acid at 0.6% concentration was included to acidify the formulation. Rubber closures, filter membranes, and liquid transfer tubing were selected on the basis of compatibility studies and absence of loss of drug due to adsorption of these components. The formulation was subjected to accelerated stability studies and dilution studies with large volume parenteral (LVP) solutions, normal saline, and 5% dextrose injection (D5W). The results of the dilution study indicated that the formulation could be diluted in these solutions up to 2 mg/mL for 8 hours without drug precipitation and degradation. Accelerated stability studies suggested that the product should be kept at 2 degrees C to 8 degrees C for long-term storage. The developed formulation was successfully scaled up and manufactured for use in clinical trials.
Krishna
G
G
Vion Pharmaceuticals, Inc, 4 Science Park, New Haven, CT 06511, USA. Gkrishna@vionpharm.com
Hodnick
W F
WF
Lang
W
W
Lin
X
X
Karra
S
S
Mao
J
J
Almassian
B
B
D000327:Adsorption; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000032:analysis / Q000737:chemistry; D004129:Dimethylpolysiloxanes; D004339:Drug Compounding; D004355:Drug Stability; D006834:Hydrazines / Q000008:administration & dosage* / Q000032:analysis / Q000737:chemistry; D006863:Hydrogen-Ion Concentration; D007263:Infusions, Parenteral; D007267:Injections; D012408:Rubber; D012828:Silicones; D012995:Solubility; D013242:Sterilization; D013449:Sulfonamides / Q000008:administration & dosage* / Q000032:analysis / Q000737:chemistry
D000970:Antineoplastic Agents; D004129:Dimethylpolysiloxanes; D006834:Hydrazines; D012828:Silicones; D013449:Sulfonamides; C483604:laromustine; C013830:baysilon; D012408:Rubber